OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Frequently asked questions
What sector does OliX PharmaceuticalsInc (226950) operate in?
OliX PharmaceuticalsInc belongs to the Energy sector and operates in the Biotechnology industry.
What is OliX PharmaceuticalsInc (226950) current stock price?
As of the latest data, OliX PharmaceuticalsInc stock price is ₩96,100, with a previous close of ₩103,300. OliX PharmaceuticalsInc lost -₩7,200 in the last trading session, representing a -6.97% loss.
What is OliX PharmaceuticalsInc (226950) current market capitalization?
OliX PharmaceuticalsInc market cap is approximately 2.19 trillion.
What is OliX PharmaceuticalsInc (226950) EBITDA?
OliX PharmaceuticalsInc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.16 billion.
Does OliX PharmaceuticalsInc (226950) pay dividends?
No. OliX PharmaceuticalsInc does not pay a dividend.
What is OliX PharmaceuticalsInc (226950) beta (volatility) score?
OliX PharmaceuticalsInc has a beta of 0.403, indicating lower volatility than the overall market.
